GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS

Transcription

1 GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: BCC Research 49 Walnut Park, Building 2 Wellesley, MA , Custom Reports: carol.laverty@bccresearch.com

2 TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1 STUDY GOALS AND OBJECTIVES 1 REASONS FOR DOING THE STUDY 1 SCOPE OF REPORT 1 MARKET ANALYSES AND FORECASTS 2 METHODOLOGY 2 INTENDED AUDIENCE 2 INFORMATION SOURCES 2 ANALYST CREDENTIALS 2 RELATED REPORTS 3 BCC ONLINE SERVICES 3 DISCLAIMER 3 CHAPTER 2 SUMMARY 5 THE DIABETES MARKET 5 LEADING COMPANIES 5 SUMMARY TABLE DIABETES MARKET BREAKDOWN BY REGIONS, THROUGH 2017 ($ SUMMARY FIGURE DIABETES MARKET EVOLUTION BY REGION, ($ 6 6 CHAPTER 3 OVERVIEW 8 DIABETES BASICS 8 STRUCTURE OF THE DIABETES MARKET 8 DRIVERS FOR GROWTH 8 RISING PREVALENCE 8 TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE, 2011 AND 2017 (CASES IN MILLIONS) NEW TECHNOLOGY 9 RATE OF MARKET GROWTH 10 CURRENT TREATMENT OF DIABETES 10 INSULIN 10 Insulin Administration Devices 10 ORAL ANTIDIABETIC DRUGS 11 MONITORING DEVICES FOR DIABETES 11 TABLE 2 TOTAL DIABETES MARKET IN 2012 ($ 11 REGIONAL SEGMENTATION 11 TABLE 3 ADULT DIABETES MARKET BY REGION (MILLIONS/%) 12 MARKET GROWTH 12 THE DIABETES INDUSTRY 12 PHARMACEUTICAL COMPANIES 12 MEDICAL DEVICE COMPANIES 13 8 CHAPTER 4 PRODUCTS AND SUPPLIERS 15 INSULIN 15 HISTORY 15 Bovine and Porcine Insulin 16

3 Humanized Insulin 16 COMPANIES SUPPLYING INSULIN 17 Eli Lilly 17 Sanofi 17 Novo Nordisk 17 Some Other Suppliers 17 Wockhardt Limited: India 17 BioconB: India 18 Shreya Life Sciences: India 18 Diosynth: the Netherlands 18 TABLE 4 MAJOR BRANDS OF INSULIN 18 INSULIN DELIVERY 19 SYRINGES 19 INSULIN SYRINGE MANUFACTURERS 19 Becton Dickinson 19 Owen Mumford 20 Terumo 20 B. Braun 20 PENS 20 TABLE 5 INSULIN PENS 21 MANUFACTURERS OF INSULIN PENS 21 Novo Nordisk 21 Owen Mumford 22 Other Makers 22 INJECTORS 22 INJECTOR MANUFACTURERS 23 Activa Brand Products 23 Antares Pharma 23 Bioject 23 MediCool Inc. 23 Owen Mumford 24 Palco Labs Inc. 24 Rosch AG Medizintechnik 24 INSULIN PUMPS 24 What Is an Insulin Pump? 24 The Infusion Set 25 Candidates for Pump Therapy 25 COMPANIES SUPPLYING INSULIN PUMPS 26 Animas Corp. 26 Sooil Development Co. 27 Medtronic MiniMed 27 Nipro Diabetes Systems 27 Roche Insulin Delivery Systems 27 Insulet 27 Tandem Diabetes Care 28 TABLE 6 INSULIN PUMPS 28 Problems with Pumps-or Users? 28

4 ORAL HYPOGLYCEMIC DRUGS 29 SULFONYLUREAS 29 TABLE 7 SULFONYLUREAS 29 BIGUANIDES 30 ALPHA-GLUCOSIDASE INHIBITOR 30 GLITAZONES 30 PRANDIAL GLUCOSE REGULATORS 30 GLP-1 ANALOGS; ALSO KNOWN AS INCRETIN MIMETICS 31 AMYLIN MIMETIC 31 TABLE 8 ORAL HYPOGLYCEMICS 32 DIAGNOSIS AND MONITORING 32 THE ROLE OF SELF-MONITORING 32 SMBG Frequency 33 BLOOD GLUCOSE MONITORING DEVICES: SUPPLIERS AND PRODUCTS 33 Lancets 34 TABLE 9 INTERNATIONAL SUPPLIERS OF BLOOD LANCETS 34 BLOOD-SAMPLING DEVICES 34 Bayer Diagnostics 34 Becton Dickinson 35 Cell Robotics 35 LifeScan 35 Roche Diagnostics 35 BLOOD GLUCOSE MONITORS Elektronika Kft 35 Abbott Laboratories 36 Acon Laboratories Inc. 36 AgaMatrix Inc. 36 Apex Biotechnology Corp. 37 Arkray USA 37 Aventir Biotech LLC 37 Bayer Corp. 37 Belbiosens 38 Diagnostic Devices Inc. 38 Eumed Biotechnology Co. Ltd. 38 GlucoPlus Inc. 38 HMD Bio Medical 38 Health & Life Co. 38 HemoCue AB 39 Home Diagnostics Inc. 39 Hypoguard 39 i-sens Inc. 39 LifeScan Inc. 39 Medtronic 39 Menarini Diagnostics 40 National Diagnostic Products 40 Novabiomedical Corp. 40 Roche 40

5 TaiDoc Technology Corp. 41 US Diagnostics Inc. 41 GLUCOSE METER ACCURACY 41 OTHER TESTING APPROACHES 42 HEMOGLOBIN A1C 42 Hemoglobin A1c Meters 42 Hemoglobin A1c Kits 43 SOFTWARE AIDS TO DIABETES MONITORING 44 AIDA On-Line 44 Bayer Care: Blood Sugar Log 44 Body Sigma 44 Dailyrating 44 DiabetEASE 44 Diabetes Assistant 45 Diabetes Homecare Center 45 Ecivon 45 HealthEngage Diabetes 45 Lifeclinic 46 PlasmaGlucose 46 Symcare 46 CHAPTER 5 NEW DEVELOPMENTS IN DIABETES 48 APPROACHES BASED ON CURRENT TECHNOLOGY 48 NOVEL INSULIN DELIVERY TECHNOLOGY 48 Oral-Lyn 48 Oramed 48 Medingo Micro-Pump Patch 48 Inhaled Insulin 49 Transdermal Approach 49 IMPROVED ORAL ANTIDIABETIC DRUGS 50 Dutogliptin 50 Byetta LAR 50 Lixisenatide 50 NEW DEVELOPMENTS IN GLUCOSE TESTING 51 Continuous Glucose Monitoring (CGM) 51 Reimbursement 52 Noninvasive Monitoring 52 TABLE 10 SELECTED COMPANIES DEVELOPING NONINVASIVE GLUCOSE MONITORING 55 Integrated Testing 56 ARTIFICIAL PANCREAS 57 Roche 57 Abbott 58 Novo Nordisk/LifeScan 58 Animas 58 RADICAL APPROACHES 59 ALTERNATIVES TO INSULIN 59 IMMUNOTHERAPY 60

6 TRANSPLANTATION 60 CELL AND STEM CELL THERAPIES 61 GENE THERAPY 62 Gene Therapy Approaches for Expressing Insulin 62 Gene Therapy Approaches for Immunomodulation 62 Gene Therapy Approaches for Cell-Based Therapies 62 A NEW AGE OF MOBILITY IN DIABETES MANAGEMENT 63 THE IMPACT OF NEW DEVELOPMENTS ON THE DIABETES MARKET 64 CHAPTER 6 THE GLOBAL DIABETES MARKET 67 MARKET COMPONENTS 67 SIZE 67 TABLE 11 GLOBAL DIABETES MARKET, 2011 ($ 67 GROWTH 68 MARKET ANALYSIS BY PRODUCT CATEGORY 68 INSULINS AND INSULIN DELIVERY DEVICES 68 Major Suppliers 69 TABLE 12 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2011 ($ MILLIONS) 69 OTHER ANTIDIABETIC DRUGS 69 Major Suppliers 69 TABLE 13 SALES OF OTHER ANTIDIABETIC DRUGS, 2011 ($ MILLIONS) 70 INSULIN PUMPS 70 TABLE 14 DIABETES MARKET BREAKDOWN BY REGION, THROUGH 2017 ($ 71 MONITORING PRODUCTS 71 Major Suppliers 71 TABLE 15 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2011 (MILLIONS/%) 71 TRENDS 71 REGIONAL SEGMENTATION 72 TABLE 16 RISING PREVALENCE OF DIABETES BY REGION, THROUGH 2017 (CASES IN MILLIONS) NATIONAL MARKETS 72 North America 73 TABLE 17 TOTAL DIABETES MARKET FOR CANADA AND THE U.S., THROUGH 2017 ($ South and Central America 74 TABLE 18 TOTAL DIABETES MARKET FOR MEXICO AND BRAZIL, THROUGH 2017 ($ Europe 74 TABLE 19 MAJOR EUROPEAN ECONOMIES: TOTAL DIABETES MARKET, THROUGH 2017 ($ Asia 75 TABLE 20 MAJOR ASIAN COUNTRIES: TOTAL DIABETES MARKET, THROUGH 2017 ($ CHAPTER 7 THE AMERICAN MARKET 77 NORTH AMERICA 77 THE U.S. 77 Vital Statistics 77

7 Health and Health Care 77 THE U.S. PHARMACEUTICAL MARKET 79 The Diabetes Market 79 TABLE 21 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2017 (CASES IN MILLIONS) 79 TABLE 22 U.S.: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 80 TABLE 23 U.S.: DIABETES DEVICES MARKET, THROUGH 2017 ($ 80 CANADA 80 Vital Statistics 80 Health and Health Care 80 CANADA'S PHARMACEUTICAL MARKET 81 The Diabetes Market 81 TABLE 24 PREVALENCE OF DIABETES IN CANADA, THROUGH 2017 (CASES IN MILLIONS) 82 TABLE 25 CANADA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 82 TABLE 26 CANADA: DIABETES DEVICES MARKET, THROUGH 2017 ($ 82 LATIN AMERICA 83 BRAZIL 83 Vital Statistics 83 Health and Health Care 83 BRAZIL'S PHARMACEUTICAL MARKET 84 The Diabetes Market 85 TABLE 27 PREVALENCE OF DIABETES IN BRAZIL, THROUGH 2017 (CASES IN MILLIONS) 85 TABLE 28 BRAZIL: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 85 TABLE 29 BRAZIL: DIABETES DEVICES MARKET, THROUGH 2017 ($ 85 MEXICO 86 Vital Statistics 86 Health and Health Care 86 MEXICO'S PHARMACEUTICAL MARKET 86 Market Resistors 87 The Diabetes Market 87 TABLE 30 PREVALENCE OF DIABETES IN MEXICO, THROUGH 2017 (CASES IN MILLIONS) 87 TABLE 31 MEXICO: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 88 TABLE 32 MEXICO: DIABETES DEVICES MARKET, THROUGH 2017 ($ 88 CHAPTER 8 THE ASIAN MARKET 90 CHINA 90 VITAL STATISTICS 90 HEALTH AND HEALTH CARE 90 CHINA'S PHARMACEUTICAL MARKET 91 DOMESTIC INDUSTRY 92 FOREIGN COMPANY INVOLVEMENT 93 IMPORTANCE OF R&D 94 CHALLENGES 94 MARKET TRENDS 94 REGULATORY CHANGES 95 THE DIABETES MARKET 96 TABLE 33 PREVALENCE OF DIABETES IN CHINA, THROUGH 2017 (CASES IN MILLIONS) 96 TABLE 34 CHINA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 97

8 TABLE 35 CHINA: DIABETES DEVICES MARKET, THROUGH 2017 ($ 97 INDIA 97 VITAL STATISTICS 97 HEALTH AND HEALTH CARE 97 GROWING AFFLUENCE-CHANGING MEDICAL NEEDS 98 REGULATORY CHANGES 98 INDIA'S PHARMACEUTICAL MARKET 98 DEMOGRAPHIC FACTORS 98 PHARMA INDUSTRY 99 PATENT REFORM 99 THE DIABETES MARKET 100 TABLE 36 PREVALENCE OF DIABETES IN INDIA, THROUGH 2017 (CASES IN MILLIONS) 100 TABLE 37 INDIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 100 TABLE 38 INDIA: DIABETES DEVICES MARKET, THROUGH 2017 ($ 101 JAPAN 101 VITAL STATISTICS 101 HEALTH AND HEALTH CARE 101 JAPAN'S PHARMACEUTICAL MARKET 102 TABLE 39 TOP SIX JAPANESE PHARMA COMPANIES, THE DIABETES MARKET 103 TABLE 40 PREVALENCE OF DIABETES IN JAPAN, THROUGH 2017 (CASES IN MILLIONS) 104 TABLE 41 JAPAN: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 104 TABLE 42 JAPAN: DIABETES DEVICES MARKET, THROUGH 2017 ($ 104 CHAPTER 9 THE EUROPEAN MARKET 106 FRANCE 106 VITAL STATISTICS 106 HEALTH AND HEALTH CARE 106 PROVISION OF HEALTH CARE 106 FRANCE'S PHARMACEUTICAL MARKET 107 THE DIABETES MARKET 107 TABLE 43 PREVALENCE OF DIABETES IN FRANCE, THROUGH 2017 (CASES IN MILLIONS) 108 TABLE 44 FRANCE: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 108 TABLE 45 FRANCE: DIABETES DEVICES MARKET, THROUGH 2017 ($ 108 GERMANY 108 VITAL STATISTICS 109 HEALTH AND HEALTH CARE 109 PROVISION OF HEALTH CARE 109 GERMANY'S PHARMACEUTICAL MARKET 109 PRICE CONTROLS 110 THE DIABETES MARKET 110 TABLE 46 PREVALENCE OF DIABETES IN GERMANY, THROUGH 2017 (CASES IN MILLIONS) 111 TABLE 47 GERMANY: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 111 TABLE 48 GERMANY: DIABETES DEVICES MARKET, THROUGH 2017 ($ 111 ITALY 111 VITAL STATISTICS 112 HEALTH AND HEALTH CARE 112

9 PROVISION OF HEALTH CARE 112 ITALY'S PHARMACEUTICAL MARKET 113 IMPLICATIONS FOR RESEARCH 114 THE DIABETES MARKET 114 TABLE 49 PREVALENCE OF DIABETES IN ITALY, THROUGH 2017 (CASES IN MILLIONS) 115 TABLE 50 ITALY: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 115 TABLE 51 ITALY: DIABETES DEVICES MARKET, THROUGH 2017 ($ 115 RUSSIA 115 VITAL STATISTICS 115 HEALTH AND HEALTH CARE 116 PROVISION OF HEALTH CARE 116 RUSSIA'S PHARMACEUTICAL MARKET 116 PHARMA THE DIABETES MARKET 117 TABLE 52 PREVALENCE OF DIABETES IN RUSSIA, THROUGH 2017 (CASES IN MILLIONS) 118 TABLE 53 RUSSIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 118 TABLE 54 RUSSIA: DIABETES DEVICES MARKET, THROUGH 2017 ($ 118 SPAIN 118 VITAL STATISTICS 119 HEALTH AND HEALTH CARE 119 PROVISION OF HEALTH CARE 119 PHARMACEUTICAL SERVICES 119 SPAIN'S PHARMACEUTICAL MARKET 120 THE DIABETES MARKET 120 TABLE 55 PREVALENCE OF DIABETES IN SPAIN, THROUGH 2017 (CASES IN MILLIONS) 121 TABLE 56 SPAIN: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 121 TABLE 57 SPAIN: DIABETES DEVICES MARKET, THROUGH 2017 ($ 121 THE UNITED KINGDOM 122 VITAL STATISTICS 122 HEALTH AND HEALTH CARE 122 PROVISION OF HEALTH CARE 122 Private Sector Involvement 122 PHARMACEUTICALS 123 THE UNITED KINGDOM'S PHARMACEUTICAL MARKET 123 THE DIABETES MARKET 124 TABLE 58 PREVALENCE OF DIABETES IN THE U.K., THROUGH 2017 (CASES IN MILLIONS) 124 TABLE 59 U.K.: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 125 TABLE 60 U.K.: DIABETES DEVICES MARKET, THROUGH 2017 ($ 125 CHAPTER 10 COMPANY PROFILES 127 LEADING COMPANIES 127 ABBOTT LABORATORIES 127 Overview 127 ABBOTT DIABETES CARE, INC. 128 BAYER AG 128 Overview 128 Diabetes Products 129

10 BECTON DICKINSON 129 Overview 129 Diabetes Products 130 BRISTOL-MYERS SQUIBB 130 Overview 130 Problems with Generics 130 Diabetes Products 130 Pipeline 131 ELI LILLY AND CO. 131 Overview 131 Diabetes Products 131 Pipeline 132 GLAXO SMITHKLINE 132 Overview 132 Diabetes Products 132 Pipeline 133 JOHNSON & JOHNSON 133 Overview 133 Diabetes Products 133 Pipeline 134 MEDTRONIC 134 Overview 134 Diabetes Products 135 Pipeline 135 MERCK & CO. LTD. 135 Diabetes 136 SmartCells 136 MERCK KGAA 137 Overview 137 Diabetes Products 137 NOVARTIS INTERNATIONAL AG 138 Overview 138 Diabetes Products 138 Research 138 NOVO NORDISK A/S 139 Overview 139 Diabetes Products 139 Pipeline 140 TABLE 61 NOVO NORDISK DIABETES PRODUCT PIPELINE 141 ROCHE 141 Overview 141 Diabetes Products 142 Blood Glucose Monitoring Systems 142 Diabetes Data Management 143 Insulin Pump Systems 143 Lancet Devices 143 Other 144

11 Pipeline 144 SANOFI 144 Overview 144 Diabetes Products 145 TAKEDA 145 Overview 145 Pipeline 146 TABLE 62 DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA 146 OTHER COMPANIES ELEKTRONIKA CO., LTD. 147 AGAMATRIX, INC. 147 ANIMAS CORP. 148 BIO-IMPEDANCE GENERAL LTD. 148 DEBIOTECH S.A. 149 INLIGHT SOLUTIONS, INC. 149 LIFESCAN, INC. 150 MANNKIND CORP. 150 A. MENARINI DIAGNOSTICS S.R.L. 151 NIPRO CORP , 151 OWEN MUMFORD LTD. 152 PALCO LABS, INC. 153 PRODIGY DIABETES CARE LLC 153 TERUMO CORP. 154 TRANSITION THERAPEUTICS INC. 154 CHAPTER 11 APPENDIX I: ABOUT DIABETES 156 BLOOD SUGAR REGULATION 156 INSULIN 156 TYPE 1 DIABETES 157 TYPE 2 DIABETES 157 GESTATIONAL DIABETES 158 OBESITY-RELATED TYPE 2 DIABETES IN CHILDREN 158 MATURE-ONSET DIABETES OF THE YOUNG (MODY) 159 OTHER DIABETIC STATES 159 LATENT AUTOIMMUNE DIABETES (LADA) 159 PREDIABETES 159 DIAGNOSIS 160 GLUCOSE TESTS 160 OFFICIAL CRITERIA 160 DIFFERENTIAL DIAGNOSIS 160 TYPE 1 DIABETES 160 TYPE 2 DIABETES 161 CURRENT TREATMENT 161 TYPE 1 DIABETES 161 TYPE 2 DIABETES 161 Sulfonylureas 162 Biguanides 162

12 Alpha-Glucosidase Inhibitors 162 Glitazones (Thiazolidinediones) 163 Prandial Glucose Regulators 163 Incretin Mimetics 163 Dipeptidyl Peptidase 4 (DPP-4) Inhibitors 163 DIET 163 MONITORING DIABETES 163 BLOOD SUGAR CONTROL 163 THE DIABETES CONTROL AND COMPLICATIONS TRIAL (DCTT) 164 GLYCATED HEMOGLOBIN (HBA1C) 165 FRUCTOSAMINE 166 PREVALENCE OF DIABETES 166 TYPE TYPE DIABETIC COMPLICATIONS 167 RETINOPATHY 168 NEUROPATHY 168 NEPHROPATHY 169 INCREASED MORTALITY RISK 169 METABOLIC SYNDROME 169 CHAPTER 12 APPENDIX 2: GLOSSARY 172 TABLE 63 GLOSSARY 172

13 LIST OF TABLES TABLE HEADING SUMMARY TABLE DIABETES MARKET BREAKDOWN BY REGIONS, THROUGH 2017 ($ TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE, 2011 AND 2017 (CASES IN MILLIONS) TABLE 2 TOTAL DIABETES MARKET IN 2012 ($ 11 TABLE 3 ADULT DIABETES MARKET BY REGION (MILLIONS/%) 12 TABLE 4 MAJOR BRANDS OF INSULIN 18 TABLE 5 INSULIN PENS 21 TABLE 6 INSULIN PUMPS 28 TABLE 7 SULFONYLUREAS 29 TABLE 8 ORAL HYPOGLYCEMICS 32 TABLE 9 INTERNATIONAL SUPPLIERS OF BLOOD LANCETS 34 TABLE 10 SELECTED COMPANIES DEVELOPING NONINVASIVE GLUCOSE MONITORING 55 TABLE 11 GLOBAL DIABETES MARKET, 2011 ($ 67 TABLE 12 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2011 ($ MILLIONS) 69 TABLE 13 SALES OF OTHER ANTIDIABETIC DRUGS, 2011 ($ MILLIONS) 70 TABLE 14 DIABETES MARKET BREAKDOWN BY REGION, THROUGH 2017 ($ 71 TABLE 15 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2011 (MILLIONS/%) 71 TABLE 16 RISING PREVALENCE OF DIABETES BY REGION, THROUGH 2017 (CASES IN MILLIONS) TABLE 17 TOTAL DIABETES MARKET FOR CANADA AND THE U.S., THROUGH 2017 ($ TABLE 18 TOTAL DIABETES MARKET FOR MEXICO AND BRAZIL, THROUGH 2017 ($ 74 TABLE 19 MAJOR EUROPEAN ECONOMIES: TOTAL DIABETES MARKET, THROUGH 2017 ($ TABLE 20 MAJOR ASIAN COUNTRIES: TOTAL DIABETES MARKET, THROUGH 2017 ($ TABLE 21 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2017 (CASES IN MILLIONS) 79 TABLE 22 U.S.: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 80 TABLE 23 U.S.: DIABETES DEVICES MARKET, THROUGH 2017 ($ 80 TABLE 24 PREVALENCE OF DIABETES IN CANADA, THROUGH 2017 (CASES IN MILLIONS) 82 TABLE 25 CANADA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 82 TABLE 26 CANADA: DIABETES DEVICES MARKET, THROUGH 2017 ($ 82 TABLE 27 PREVALENCE OF DIABETES IN BRAZIL, THROUGH 2017 (CASES IN MILLIONS) 85 TABLE 28 BRAZIL: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 85 TABLE 29 BRAZIL: DIABETES DEVICES MARKET, THROUGH 2017 ($ 85 TABLE 30 PREVALENCE OF DIABETES IN MEXICO, THROUGH 2017 (CASES IN MILLIONS) 87 TABLE 31 MEXICO: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 88 TABLE 32 MEXICO: DIABETES DEVICES MARKET, THROUGH 2017 ($ 88 TABLE 33 PREVALENCE OF DIABETES IN CHINA, THROUGH 2017 (CASES IN MILLIONS) 96 TABLE 34 CHINA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 97 TABLE 35 CHINA: DIABETES DEVICES MARKET, THROUGH 2017 ($ 97 TABLE 36 PREVALENCE OF DIABETES IN INDIA, THROUGH 2017 (CASES IN MILLIONS) 100 TABLE 37 INDIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 100 TABLE 38 INDIA: DIABETES DEVICES MARKET, THROUGH 2017 ($ 101 TABLE 39 TOP SIX JAPANESE PHARMA COMPANIES, TABLE 40 PREVALENCE OF DIABETES IN JAPAN, THROUGH 2017 (CASES IN MILLIONS) 104 TABLE 41 JAPAN: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($

14 TABLE HEADING TABLE 42 JAPAN: DIABETES DEVICES MARKET, THROUGH 2017 ($ 104 TABLE 43 PREVALENCE OF DIABETES IN FRANCE, THROUGH 2017 (CASES IN MILLIONS) 108 TABLE 44 FRANCE: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 108 TABLE 45 FRANCE: DIABETES DEVICES MARKET, THROUGH 2017 ($ 108 TABLE 46 PREVALENCE OF DIABETES IN GERMANY, THROUGH 2017 (CASES IN MILLIONS) 111 TABLE 47 GERMANY: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 111 TABLE 48 GERMANY: DIABETES DEVICES MARKET, THROUGH 2017 ($ 111 TABLE 49 PREVALENCE OF DIABETES IN ITALY, THROUGH 2017 (CASES IN MILLIONS) 115 TABLE 50 ITALY: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 115 TABLE 51 ITALY: DIABETES DEVICES MARKET, THROUGH 2017 ($ 115 TABLE 52 PREVALENCE OF DIABETES IN RUSSIA, THROUGH 2017 (CASES IN MILLIONS) 118 TABLE 53 RUSSIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 118 TABLE 54 RUSSIA: DIABETES DEVICES MARKET, THROUGH 2017 ($ 118 TABLE 55 PREVALENCE OF DIABETES IN SPAIN, THROUGH 2017 (CASES IN MILLIONS) 121 TABLE 56 SPAIN: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 121 TABLE 57 SPAIN: DIABETES DEVICES MARKET, THROUGH 2017 ($ 121 TABLE 58 PREVALENCE OF DIABETES IN THE U.K., THROUGH 2017 (CASES IN MILLIONS) 124 TABLE 59 U.K.: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ 125 TABLE 60 U.K.: DIABETES DEVICES MARKET, THROUGH 2017 ($ 125 TABLE 61 NOVO NORDISK DIABETES PRODUCT PIPELINE 141 TABLE 62 DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA 146 TABLE 63 GLOSSARY 172

15 LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE DIABETES MARKET EVOLUTION BY REGION, ($ 6